However, Shlimak noted adjusted gross margin declined compared with the first three quarters of 2025. She said that was largely due to “adverse production quality mix” at GrowCo as the company worked through an expansion, along with expense timing that impacted cost of goods sold during the ramp-up.Fourth-quarter gross profit and adjusted gross profit were $16.2 million, representing a 36% margin and a 670-basis-point improvement versus the 30% adjusted gross margin in Q4 2024. Shlimak said the year-over-ye ...

Top 3 Canadian Cannabis Stocks to Watch in February 2026The Canadian cannabis sector continues to evolve in early 2026. Although volatility remains, investor interest is returning. Regulatory discussions in the United States are once again gaining momentum. Because of that, Canadian operators with U.S. exposure are drawing attention. Many investors are watching companies positioned for cross-border expansion.Canada remains a mature recreational market. However, growth there has slowed compared to earlier ye ...

Wall Street can be very unforgiving. Unfortunately, a stock doesn't remember prices it once traded at -- and prices can keep rising or falling. Investors have seen this firsthand with Tilray Brands (NASDAQ: TLRY), a once-promising cannabis stock. Its shares have declined 16% over the past year. Even worse, the stock is down by 74% over the past three years and 97% over the past five years. Why has Tilray stock struggled, and is it time that investors dump their shares? Where to invest $1,000 right now? Ou ...

Industry Overview - The U.S. cannabis sector is adjusting as February 2026 approaches, with a shift in focus towards sustainability and execution rather than rapid expansion [1] - Higher interest rates have prompted companies to reassess spending habits, making balance sheet strength increasingly important [1] - Revenue quality is prioritized over headline growth figures, with companies generating consistent sales standing out [1] Market Dynamics - State-level legalization continues to expand, with several markets maturing into stable revenue generators, providing predictable consumer demand [2] - Medical and adult-use programs are key growth drivers, while federal reform discussions linger as a potential catalyst for the sector [2] - Uncertainty regarding federal reform limits institutional participation in the cannabis market [2] Investor Behavior - Retail investors play a critical role in cannabis trading volume, with February marking renewed interest after year-end repositioning [3] - Tax-loss selling pressure typically fades by February, allowing fundamentally sound stocks to attract attention [3] - Dispensary count and geographic exposure are key evaluation metrics, with diversified operators reducing market-specific risk [3] Financial Discipline - Financial discipline is essential for long-term survival, with companies generating real revenue gaining investor credibility [4] - Companies relying on speculation face increasing pressure, highlighting the importance of operational efficiency and cost management [4] Company Profiles Planet 13 Holdings Inc. (PLNH) - Operates as a vertically integrated cannabis retailer, known for its large Las Vegas dispensary that attracts both tourists and locals [5][6] - Emphasizes experiential retail, blending entertainment and product selection to differentiate from traditional dispensaries [5] - Operates over ten dispensaries nationwide and produces its own cannabis products, targeting premium consumers [6][9] - Revenue has fluctuated due to pricing pressure, but the company continues to generate meaningful quarterly sales [9] - Management focuses on reducing operating expenses and improving margins while monitoring same-store sales trends [10][11] FLUENT Corp. (CNTMF) - Operates as a regional cannabis company with a significant presence in Florida, one of the largest medical cannabis markets [11][12] - Emphasizes controlled expansion and brand consistency, operating over thirty dispensaries nationwide [12][14] - Generates over $100 million in annual revenue, with modest growth affected by pricing pressure [14] - Management focuses on operational efficiency and improving liquidity, with moderate debt levels compared to larger peers [15] Verano Holdings Corp. (VRNOF) - One of the largest cannabis operators in the U.S., with a strong presence in states like Illinois and Florida [16][17] - Operates over 150 dispensaries and owns several cultivation facilities, supporting supply chain control [17][19] - Generates substantial revenue but continues to report net losses due to pricing pressure and elevated operating costs [19] - Management is focused on cost optimization and selective retail expansion, with future profitability dependent on margin recovery [20]

Core Insights - The cannabis industry, particularly in Canada and the U.S., has seen significant growth since legalization, but companies like Canopy Growth Corp. are struggling despite rising cannabis use [1][2]. Company Overview - Canopy Growth Corp. had a market cap peak of nearly $18 billion from 2017 to 2019 but has since faced disastrous investment results, with its current market cap at $372 million [2][3]. - The stock price has dramatically decreased, currently at $1.11, down 99.8% from its all-time high [3][11]. Business Strategy and Execution - Canopy Growth's aggressive expansion into the U.S. and Europe, along with diversification into cannabis-related products, has been criticized as overly ambitious [4]. - The company made significant missteps, including misreading the cannabis market and rushing its expansion, leading to reliance on stock and debt issuance rather than funding through profits [5]. Financial Performance - Canopy Growth continues to lose money, with a share count increase of over 3,700%, resulting in substantial stock dilution [6]. - The company recently acquired MTL Cannabis for $125 million, despite its inability to afford such acquisitions, raising concerns about its financial health [8]. Industry Context - The legalized cannabis market has proven challenging, with many cannabis stocks underperforming and several companies facing heavy losses or going bankrupt [10]. - The overall sentiment suggests that not all growing industries guarantee investment success, as evidenced by Canopy Growth's struggles [10].

Core Viewpoint - The Cannabist Company Holdings Inc. has entered into an agreement to sell its Virginia subsidiary, Green Leaf Medical of Virginia, LLC, for a total consideration of $130 million, following a go-shop process that identified a superior acquisition proposal [1][8]. Transaction Details - The sale involves the purchase of all equity interests of Green Leaf Virginia for $130 million, with $117.5 million payable in cash at closing and $12.5 million held in escrow for post-closing adjustments [3]. - The transaction is subject to certain closing conditions, including regulatory approvals, and is expected to close early in 2026 [4]. Financial Implications - The company plans to use a portion of the net proceeds from the transaction to redeem its Senior Secured Notes [5]. Strategic Review - A special committee of independent directors has been formed to explore strategic alternatives, including asset sales and mergers, in light of ongoing operational and financial challenges [9]. Background Information - The Cannabist Company, formerly known as Columbia Care, operates 77 facilities across 12 U.S. jurisdictions, including 61 dispensaries and 16 cultivation and manufacturing facilities [11].

Core Viewpoint - Cronos Group Inc. is acquiring CanAdelaar B.V. for an up-front cash consideration of US$67.0 million, plus additional cash earnouts based on normalized EBITDA for 2026 and 2027, positioning Cronos as the market leader in the Netherlands' adult-use cannabis market [1][2]. Transaction Overview - The acquisition involves an up-front payment of €57.5 million (US$67.0 million), representing approximately 1.4 times CanAdelaar's last twelve months (LTM) revenue and 2.4 times LTM EBITDA [1][8]. - The transaction is expected to close in early 2026, pending regulatory approvals in the Netherlands [9]. Strategic Rationale - The acquisition is seen as financially compelling and strategically important for establishing a footprint in Europe and leveraging investments in borderless products [2][12]. - CanAdelaar is the largest cannabis company in the Netherlands' adult-use cannabis pilot program, known as the Wietexperiment, which is designed to create a regulated cannabis supply chain [3][4]. Market Context - The Wietexperiment was enacted in 2020 and officially launched in April 2025, allowing for the sale of cannabis in ten municipalities, with the potential for expansion [3][12]. - CanAdelaar has a current cultivation yield of approximately 20,000 kg of dried flower annually and is the only industrial-scale greenhouse cultivator in the Wietexperiment [6][12]. Financial Performance - CanAdelaar's revenue is projected to grow from US$17.7 million in 2024 to US$47.3 million for the twelve months ending September 30, 2025 [6]. - EBITDA is expected to increase from US$8.0 million in 2024 to US$28.2 million for the twelve months ending September 30, 2025 [7]. Competitive Positioning - CanAdelaar holds the leading market share within the Wietexperiment, with active sales to nearly all 72 coffee shops involved in the program [5][12]. - The regulatory framework of the Wietexperiment is designed to promote responsible adult use, potentially serving as a model for other countries [12].

Core Insights - The Canadian cannabis sector is experiencing renewed interest from traders and long-term investors despite unpredictable market conditions, with leading companies showing resilience and strategic progress [1][2] - The industry faces challenges such as slower domestic growth, tighter financing conditions, and heavy price competition, but operators are expanding internationally and preparing for potential U.S. policy changes [1][2] - Financial discipline is becoming a key theme, with companies reducing costs and improving margins, indicating signs of maturity in the sector [3] Industry Overview - The global cannabis landscape is evolving, with European countries expanding medical programs and Germany advancing legalization, creating export opportunities for Canadian producers [2] - U.S. federal reform remains uncertain, but companies with indirect exposure to the U.S. market could benefit from any policy changes [2] Company Highlights - **Tilray Brands, Inc.**: Continues to expand internationally while improving financial performance, reporting Q1 fiscal 2026 revenue of approximately $210 million, with positive net income and over $250 million in cash [5][8] - **Canopy Growth Corporation**: Gaining traction after restructuring, with Q2 fiscal 2026 revenue growth driven by Canadian adult-use sales and improved medical demand, alongside a significant reduction in net loss [9][10][11] - **Village Farms International, Inc.**: Transitioned to cannabis cultivation with strong financial performance, reporting double-digit revenue growth and positive net income for multiple quarters, supported by efficient operations and rising international demand [12][14] Financial Performance - Tilray's revenue growth is attributed to stronger Canadian sales and rising international demand, with improved margins and better cost control [8] - Canopy's revenue growth is driven by better brand strength and retail penetration in Canada, with improved gross margins and liquidity [10][11] - Village Farms has shown strong financial performance with high gross margins and positive net income, benefiting from disciplined cost controls and scalable growing capacity [14] Strategic Positioning - Companies are building stronger platforms and expanding their international footprints, positioning themselves for potential U.S. policy shifts [1][2] - Tilray's diverse product portfolio and strong distribution network in Canada and Europe position it well for future growth [5] - Canopy's integrated platform in the U.S. through partnerships provides a strong multi-state reach despite not holding direct cannabis licenses [9][11] - Village Farms' international presence and potential for THC production in the U.S. could enhance its growth prospects [12][14]

Core Insights - Cronos Group Inc. achieved record levels of consolidated net revenue, gross profit, and Adjusted EBITDA in Q3 2025, with net revenue increasing by 9% quarter-over-quarter and 6% year-over-year [1][2] - The company reported record-high net revenue in Israel, where its PEACE NATURALS brand remains the number one cannabis brand [1][2] - Cronos Group maintains a strong balance sheet with $824 million in total cash and cash equivalents and short-term investments [1][3] Financial Performance - Net revenue for Q3 2025 was $36.3 million, an increase of $2.1 million from Q3 2024, primarily driven by higher cannabis flower sales in Israel and cannabis extract sales in Canada [10] - Gross profit for Q3 2025 was $18.3 million, up $14.7 million from Q3 2024, attributed to lower inventory step-up costs and higher average sales prices [10][7] - Adjusted EBITDA improved to $5.7 million in Q3 2025, an increase of $11.7 million from Q3 2024, driven by higher gross profit and lower operating expenses [10][7] Market Position - The Spinach brand ended Q3 2025 as the second most popular brand in Canada, holding a 4.5% total market share, and ranked 1 in edibles with a 19.7% market share [11][12] - PEACE NATURALS continues to be the top-performing brand in Israel, achieving record net revenue and sales volume in Q3 2025 [15][16] - International results outside of Israel were modest due to shipment timing, with expectations for second-half performance to align closely with the first half [16] Brand and Product Updates - The Spinach brand launched new products, including SOURZ by Spinach Fully Blasted gummies and limited-edition flavors, reinforcing its leadership in innovative cannabis edibles [12] - Cronos Group's expansion of Cronos GrowCo is complete, with sales from the expansion expected to fuel growth in 2026 [17] - The company introduced new strains under the PEACE NATURALS brand in Israel, reflecting its advanced genetic breeding program and cultivation capabilities [15]

Cannara Biotech Conference Summary Company Overview - **Company Name**: Cannara Biotech Inc. - **Stock Symbol**: LOVE (TSXV) - **Industry**: Canadian Cannabis - **Founded**: 2018 - **Headquarters**: Quebec, Canada - **Facilities**: Operates over 1.6 million square feet across two fully owned facilities in Quebec [2][5] Core Business and Market Position - Cannara Biotech is a vertically integrated cannabis company focused on producing premium-grade cannabis at scale, emphasizing profitability, innovation, and long-term value creation [2][4] - Currently the **seventh largest producer** in Canada by sales and **second largest** in Quebec, with a **12.8% market share** in Quebec, up from 9.7% a year ago [5][17] - Annualized production run rate is approximately **50,000 kilograms** (50 million grams) [5][6] Financial Performance - **Q3 2025**: Best quarterly financial results in the company's history - **Nine months of 2025**: - Net revenue: **$80 million** - Gross profit: **$32.7 million** - Gross margin: **41%**, with steady quarter-over-quarter increases [9][10] - Adjusted EBITDA: **$20.7 million** (26% of revenues) [10] - Net income: **$9.8 million**, a **53% increase** from the previous year [10] - **Cash Flow**: Generated **$17.2 million** in operating cash flow and **$12.3 million** in free cash flow in the first nine months of 2025 [11] Operational Highlights - Achieved a **26% increase** in capacity over the past year without additional capital costs [6][9] - Vertical integration allows full control over the cannabis supply chain, enhancing quality and efficiency [7][24] - Upcoming launch of a new vape category in Quebec, with **20% retail shelf space** already secured [8][17] Competitive Advantages - Strong operational platform with a focus on premium quality, scalable operations, and cost leadership [8][9] - Access to Quebec's low electricity rates of **$0.059 per kilowatt**, significantly lower than other provinces [26] - High barriers to entry in Quebec due to strict regulations on sales and marketing, allowing Cannara to thrive without heavy promotional activities [26][27] Strategic Initiatives - Plans for a **$10 million investment** in a new dedicated processing center to support growth and expand capacity to **100,000 kilograms** annually [16][24] - Focus on internal growth rather than external acquisitions, emphasizing operational discipline and quality [25][27] Market Trends and Outlook - The Canadian cannabis market is experiencing a shift, with a **41% surge** in estimated retail sales year-over-year, positioning Cannara as a leader in growth [16][17] - The company is well-prepared to meet unserved demand and capitalize on upcoming market opportunities, particularly in the vape segment [8][17] Conclusion - Cannara Biotech is positioned as a dominant player in the Canadian cannabis market, with a strong financial performance, operational efficiencies, and a clear growth strategy focused on quality and innovation [2][9][27]